Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1533-1538

  Rogóz, Zofia ^a   Kabziński, Marcin ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressant drugs; Forced swimming test; Mice; Risperidone

Indexed keywords

FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; REBOXETINE; RISPERIDONE; SERTRALINE; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANTIIMMOBILITY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; RECEPTOR BLOCKING; TREATMENT RESPONSE;

EID: 84857495768     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70717-4     Document Type: Article

References (23)

1. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371-386. (Pubitemid 26184108)
2. Dhir A, Kulkarni SK: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83-88.
3. Dremenkov E, Mansari EM, Blier P: Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry, 2007, 61, 671-678.
4. Hatanake K, Nomura T, Hidaka K, Takeuchi H, Yatsugi S, Fujii M, Yamaguchi T: Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Neuropharmacology, 1996, 35, 1621-1626. (Pubitemid 27026491)
5. Hirose S, Ashby CR: An open pilot study combining risperidone and selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry, 2002, 63, 733-736.
6. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY: Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology, 2006, 185, 274-281.
7. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebocontrolled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205-214.
8. Korstein SG, Schneider RK: Clinical festures of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 16, 18-25.
9. Kumar R, Palit G, Dhawan BN: Comparative behavioral effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol, 2003, 462, 133-138. (Pubitemid 36183744)
10. Nierenberg AA, Amsterdam JD: Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry, 1990, 51, 39-47. (Pubitemid 20212863)
11. Nowakowska E, Kuś K, Polański A, Burda K, Nowakowska A, Sadowski C: Concomitant use of carbamazepine and olanzapine and the effect on some behavioral functions in rats. Pharmacol Rep, 2011, 63, 372-380.
12. O'Connor M, Silver H: Additing risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol, 1998, 18, 89-91. (Pubitemid 28045644)
13. Ostroff RB, Nelson J: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 1999, 60, 256-259. (Pubitemid 29193925)
14. Pomierny-Chamioło L, Poleszak E, Pilc A, Nowak G: NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep, 2010, 62, 1186-1190.
15. Porsolt RD, Bertin A, Jalfre M: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther, 1977, 229, 327-336. (Pubitemid 8225714)
16. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I et al.: Effects of risperidone augmentation in patients with treatmentresistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2006, 31, 2505-2513. (Pubitemid 44607069)
17. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29-39.
18. Rogóż Z: Effects of co-treatment with mirtazapine and low doses of risperidone on the immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191-1196.
19. Rogóż Z: Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacol Rep, 2009, 61, 1173-1178.
20. Salmerón JM, Alcántara AG, Barcia D: Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder. Actas Luco Esp Neurol Psiquiatr Cienc Afines (Spanish), 1998, 26, 399-402.
21. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K et al.: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 1996, 124, 57-73. (Pubitemid 26112775)
22. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57-61.
23. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatry Scand, 2008, 117, 253-259. (Pubitemid 351350599)